CN115025150B - 一种治疗炎症性皮肤病的中药组合物、洗剂 - Google Patents
一种治疗炎症性皮肤病的中药组合物、洗剂 Download PDFInfo
- Publication number
- CN115025150B CN115025150B CN202210831353.0A CN202210831353A CN115025150B CN 115025150 B CN115025150 B CN 115025150B CN 202210831353 A CN202210831353 A CN 202210831353A CN 115025150 B CN115025150 B CN 115025150B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- lotion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 113
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 239000006210 lotion Substances 0.000 title claims abstract description 27
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 14
- 244000178870 Lavandula angustifolia Species 0.000 claims abstract description 19
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims abstract description 19
- 239000001102 lavandula vera Substances 0.000 claims abstract description 18
- 235000018219 lavender Nutrition 0.000 claims abstract description 18
- 235000013399 edible fruits Nutrition 0.000 claims description 20
- 241000931143 Gleditsia sinensis Species 0.000 claims description 17
- 241000334154 Isatis tinctoria Species 0.000 claims description 17
- 240000002924 Platycladus orientalis Species 0.000 claims description 17
- 240000007164 Salvia officinalis Species 0.000 claims description 17
- 235000005412 red sage Nutrition 0.000 claims description 17
- 240000000249 Morus alba Species 0.000 claims description 16
- 235000008708 Morus alba Nutrition 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000002994 raw material Substances 0.000 claims description 12
- 244000144886 lesser spear grass Species 0.000 claims description 4
- 241000205585 Aquilegia canadensis Species 0.000 claims 3
- 201000004384 Alopecia Diseases 0.000 abstract description 28
- 210000004761 scalp Anatomy 0.000 abstract description 26
- 230000000694 effects Effects 0.000 abstract description 18
- 231100000360 alopecia Toxicity 0.000 abstract description 16
- 208000003251 Pruritus Diseases 0.000 abstract description 15
- 210000003128 head Anatomy 0.000 abstract description 15
- 201000004681 Psoriasis Diseases 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 10
- 230000007803 itching Effects 0.000 abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 6
- 230000002588 toxic effect Effects 0.000 abstract description 6
- 206010012438 Dermatitis atopic Diseases 0.000 abstract description 4
- 201000008937 atopic dermatitis Diseases 0.000 abstract description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 abstract description 3
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 238000000222 aromatherapy Methods 0.000 abstract 1
- 238000007670 refining Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 60
- 239000007788 liquid Substances 0.000 description 30
- 241001570521 Lonicera periclymenum Species 0.000 description 21
- 210000004209 hair Anatomy 0.000 description 17
- 208000001840 Dandruff Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 238000001035 drying Methods 0.000 description 7
- 230000003676 hair loss Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 208000024963 hair loss Diseases 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000001061 forehead Anatomy 0.000 description 5
- 238000003672 processing method Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000003287 bathing Methods 0.000 description 4
- 239000003124 biologic agent Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 210000003780 hair follicle Anatomy 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010048768 Dermatosis Diseases 0.000 description 3
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 3
- 206010068168 androgenetic alopecia Diseases 0.000 description 3
- 201000002996 androgenic alopecia Diseases 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000015817 Infant Nutrition disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 244000090896 Nigella sativa Species 0.000 description 2
- 235000016698 Nigella sativa Nutrition 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 102000001307 androgen receptors Human genes 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000002647 laser therapy Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001711 nigella sativa Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000013077 scoring method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241001621841 Alopecurus myosuroides Species 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000576429 Forsythia suspensa Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 244000167230 Lonicera japonica Species 0.000 description 1
- 235000017617 Lonicera japonica Nutrition 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241001518085 Nigella glandulifera Species 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 241000669298 Pseudaulacaspis pentagona Species 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 206010052568 Urticaria chronic Diseases 0.000 description 1
- 240000006677 Vicia faba Species 0.000 description 1
- 235000010749 Vicia faba Nutrition 0.000 description 1
- 235000002098 Vicia faba var. major Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008195 breast development Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000024376 chronic urticaria Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000011869 dried fruits Nutrition 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 230000003648 hair appearance Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000011726 slow pulse Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/14—Cupressaceae (Cypress family), e.g. juniper or cypress
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种治疗炎症性皮肤病的中药组合物以及由该中药组合物制备得到的中药洗剂,属于中药技术领域,本发明基于头皮炎症性皮肤病患者多因风湿热邪熏蒸,上达巅顶,以清热祛湿,疏风止痒为法,并应用治疗脱发的特色药物黑种草子以及芳香疗法代表药物薰衣草精制而成,能有效治疗头部银屑病、脂溢性皮炎、脂溢性脱发、特应性皮炎等炎症性皮肤病,且无毒副作用。
Description
技术领域
本发明涉及中药技术领域,特别涉及一种治疗炎症性皮肤病的中药组合物、洗剂。
背景技术
炎症性皮肤病是皮肤科最大的一类疾病,是由于免疫系统失调导致皮肤组织破坏而引起的一组疾病,包括银屑病、特应性皮炎、脂溢性皮炎、慢性荨麻疹等,尤其是银屑病和特应性皮炎,银屑病的发病率在世界范围为1%-3%,我国成人特应性皮炎的发病率约为5%,儿童发病率高达8%~10%。这些疾病临床表现迥异,分类不同,但现在人们意识到这些疾病有共同的特点—炎症,包括由T细胞所介导的和由抗原-抗体所介导的炎症。传统治疗模式特异性低、易复发、不良反应相对较大,或病程太长患者容易失去信心。20世纪以来,皮肤疾病进入生物治疗阶段,生物制剂涵盖了很多皮肤科难治的疾病,并取得了很多明确的效果,但不同种类的生物制剂也存在禁忌症与不良反应。同时,生物制剂价格昂贵,使其在临床的应用推广受到了限制。
头皮是银屑病的好发部位,80%的银屑病患者伴有头皮损害,皮损可见边界清楚,覆有鳞屑性红斑,皮损处毛发呈束状。由于发病部位的特殊性、鳞屑、瘙痒明显,头皮银屑病严重影响患者身心健康,降低生活质量。头皮银屑病的主要治疗方法有局部维生素制剂D3类似物、皮质类固醇、窄谱中波紫外线(NB-UVB)等。外用糖皮质激素虽是治疗头皮银屑病的常用治疗手段,但激素的不良反应、停药后反复限制了其应用,导致患者治疗依从性和治疗效果差。
脂溢性脱发又被称为雄激素性脱发、男性型秃发、早秃。该病发病以20-30岁的青年为主,对患者的身体健康和精神状况影响较大。本病患者经常有明显的头皮皮脂溢出、瘙痒伴有过度头皮屑、头发油腻等。男性患者主要从前额两侧头发开始变稀疏、变细,可以向头顶延伸,额部发际线缓慢后移,或直接从头顶部开始脱发;女性患者主要表现为头顶部头发成片脱落,额角发际线一般不会后移。最近的研究表明,脂溢性脱发的发生与遗传、血清雄激素水平、雄激素受体的分布及敏感度、头皮皮下血流、内分泌功能和社会心理因素有关。主要治疗手段包括:①口服非那雄胺、螺内酯,以降低头皮以及血清中的二氢睾酮水平或减少二氢睾酮与雄激素受体的结合比例;②口服雄激素拮抗药,主要有雌激素,不良反应为男性性欲低下、乳房发育;③激光疗法;④外用米诺地尔;⑤外科手术种植毛囊等。脂溢性脱发的西药治疗作用机理清晰、疗效确切,但临床报告不良反应较多。手术治疗虽见效快,但仍避免不了术后再脱落及遗留疤痕的问题,低能量激光疗法也存在研究不充分的问题。
总之,无论是头皮部位的银屑病还是脂溢性脱发,西药治疗或手术都存在副作用大的问题。
发明内容
有鉴于此,本发明目的在于提供一种治疗炎症性皮肤病的中药组合物、洗剂,本发明提供的中药组合物可有效治疗头皮部位的银屑病和脂溢性脱发,且副作用小。
为了实现上述目的,本发明提供以下技术方案:
本发明提供了一种治疗炎症性皮肤病的中药组合物,由以下重量份的原料组成:金银花15~50份、侧柏叶15~40份、大青叶15~40份、连翘25~40份、桑叶15~30份、薰衣草15~50份、黑种草子15~30份、丹参15~40份、皂角25~50份。
优选地,所述中药组合物由以下重量份的原料组成:金银花15~25份、侧柏叶15~25份、大青叶15~25份、连翘25~35份、桑叶15~25份、薰衣草15~25份、黑种草子15~25份、丹参15~25份、皂角25~35份。
优选地,所述中药组合物由以下重量份的原料组成:金银花20份、侧柏叶20份、大青叶20份、连翘30份、桑叶20份、薰衣草20份、黑种草子20份、丹参20份、皂角30份。
本发明还提供了一种治疗炎症性皮肤病的中药洗剂,由以下方法制备得到:
将所述中药组合物与水混合进行煎煮,所得煎煮液为中药洗剂。
优选地,所述中药组合物与水的用量比为155g:1500~3000mL。
优选地,所述中药组合物与水混合后浸泡1~2h再进行煎煮。
优选地,所述煎煮的时间为15~20min。
有益技术效果:本发明提供了治疗炎症性皮肤病的中药组合物以及由该中药组合物制备得到的中药洗剂,本发明基于头皮炎症性皮肤病患者多因风湿热邪熏蒸,上达巅顶,以清热祛湿,疏风止痒为法,并应用维吾尔医学治疗脱发的特色药物黑种草子以及芳香疗法代表药物薰衣草精制而成,能有效治疗头部银屑病、脂溢性皮炎、脂溢性脱发、特应性皮炎等炎症性皮肤病,且无毒副作用。
具体实施方式
本发明提供了一种治疗炎症性皮肤病的中药组合物,由以下重量份的原料组成:金银花15~50份、侧柏叶15~40份、大青叶15~40份、连翘25~40份、桑叶15~30份、薰衣草15~50份、黑种草子15~30份、丹参15~40份、皂角25~50份。
按重量份计,本发明所述中药组合物包括金银花15~50份,优选为20~40份,更优选为25~35份。
在本发明中,所述金银花优选为忍冬科植物忍的干燥花蕾或带初开的花;所述金银花的炮制方法为除去杂质。本发明所述金银花为君药,甘,寒。清热解毒,凉散风热,可解诸疮。《生草药性备要》记载:“能消痈疽疔毒,止痢疾,洗疳疮,去皮肤血热。
以金银花的用量为基准,按重量份计,本发明所述中药组合物包括侧柏叶15~40份,优选为20~30份,更优选为25份。
在本发明中,所述侧柏叶为柏科植物侧柏的干燥枝梢和叶;所述侧柏叶的炮制方法为除去硬梗及杂质。本发明所述侧柏味苦、涩,寒,入肺、肝、脾,凉血止血,生发乌发,可清血分之热。《本草正》记载:“善清血凉血,去湿热湿痹,骨节疼痛。捣烂可敷火丹,散痄腮肿痛热毒。”
以金银花的用量为基准,按重量份计,本发明所述中药组合物包括大青叶15~40份,优选为20~30份,更优选为25份。
在本发明中,所述大青叶为十字花科植物菘蓝的干燥叶;所述大青叶的炮制方法为除去杂质,略洗,切碎,干燥。本发明所述大青叶苦,寒,入心、胃经,可清热解毒,凉血消斑。《本草正》记载:“治瘟疫热毒发狂,风热斑疹,痈疡肿痛,除烦渴,止鼻衄、吐血,杀疳蚀、金疮箭毒。凡以热兼毒者,皆宜蓝叶捣汁用之。”
以金银花的用量为基准,按重量份计,本发明所述中药组合物包括连翘25~40份,更优选为30~35份。
在本发明中,所述连翘为木犀科植物连翘的干燥果实;所述连翘的炮制方法为拣净杂质,搓开,除去枝梗。本发明所述连翘苦,微寒。清热解表,消肿散结。《本草纲目》记载:“连翘状似人心,……厥阴包络气分主药也。诸痛痒疮疡皆心火,故为十二经疮家圣药,而兼治手足少阳,手阳的三经气方之热也。”
以金银花的用量为基准,按重量份计,本发明所述中药组合物包括桑叶15~30份,更优选为20~25份。
在本发明中,所述桑叶为桑科植物桑的干燥叶;所述桑叶的炮制方法为初霜后采收,除去杂质,晒干。本发明所述桑叶苦,凉。疏散风热,清肺润燥,清肝明目,《本草纲目》记载:“治劳热咳嗽,明目,长发。”
以金银花的用量为基准,按重量份计,本发明所述中药组合物包括薰衣草15~50份,更优选为20~40份,最优选为25~30份。
在本发明中,所述薰衣草为狭叶薰衣草的干燥地上部分;本发明所述薰衣草辛,凉,清热解毒,散风止痒。维吾尔医称薰衣草为乌斯提乎杜思,认为薰衣草性质为二级湿热,具有消散寒气,燥湿止痛功效,浴剂可治疗风湿病,油剂可做缓和的兴奋剂和驱风剂。
以金银花的用量为基准,按重量份计,本发明所述中药组合物包括黑种草子15~30份,优选为20~25份。
在本发明中,所述黑种草子为毛茛科植物腺毛黑种草的干燥成熟种子;所述黑种草子的炮制方法为夏、秋二季果实成熟时采割植株,晒干,打下种子,除去杂质,晒干。本发明所述黑种草子甘,辛,温。为维吾尔族医学治疗脱发的代表药物之一,具有生发、育发、固发、乌发之功能,它是通过加强头皮及毛囊的营养,促进头皮及毛囊对营养物的吸收与利用,以及头皮代谢废物的排泄,增加毛囊的摄住力而发挥作用,可消肿,驱肠气,通经,健胃筋,健体,催乳,利尿。
以金银花的用量为基准,按重量份计,本发明所述中药组合物包括丹参15~40份,优选为20~35份,更优选为25~30份。
在本发明中,所述丹参为唇形科植物丹参的干燥根和根茎;所述丹参的炮制方法为春、秋二季采挖,除去泥沙,干燥。本发明所述丹参苦,微寒。入心、肝经。祛瘀止痛,活血通经,清心除烦。
以金银花的用量为基准,按重量份计,本发明所述中药组合物包括皂角25~50份,优选为30~45份,更优选为30~40份。
在本发明中,所述皂角为豆科植物皂荚的干燥成熟果实;所述皂角的炮制方法为秋季果实成熟时采摘,晒干。本发明所述皂角辛,温,微毒。祛风痰,除湿毒,杀虫。《马敬思自得录方》记载:“治风癣疥癞或皮肤麻木,死肌,风痹顽皮等证。”
在本发明中,所述中药组合物优选由以下重量份的原料组成:金银花15~25份、侧柏叶15~25份、大青叶15~25份、连翘25~35份、桑叶15~25份、薰衣草15~25份、黑种草子15~25份、丹参15~25份、皂角25~35份。
在本发明中,所述中药组合物优选由以下重量份的原料组成:金银花20份、侧柏叶20份、大青叶20份、连翘30份、桑叶20份、薰衣草20份、黑种草子20份、丹参20份、皂角30份。
本发明还提供了一种治疗炎症性皮肤病的中药洗剂,由以下方法制备得到:将所述中药组合物与水混合进行煎煮,所得煎煮液为中药洗剂。
本发明将所述中药组合物与水混合进行煎煮,所得煎煮液为中药洗剂。
在本发明中,所述中药组合物与水的用量比优选为155g:1500~3000mL,更优选为155g:2000~2500mL;所述中药组合物与水混合后优选浸泡1~2h再进行煎煮,更优选为浸泡1.5h;所述煎煮的时间优选为15~20min。
为了更好地理解本发明,下面结合实施例进一步阐明本发明的内容,但本发明的内容不仅仅局限于下面的实施例。
实施例1
一种治疗炎症性皮肤病的中药组合物,由以下重量份数的原料组成:金银花15份、侧柏叶15份、大青叶15份、连翘25份、桑叶15份、薰衣草15份、黑种草子15份、丹参15份、皂角25份。
取上述中药组合物155g,加入2500mL水,浸泡1h,慢火煮开后熬制15min,固液分离,得到第一药液和药渣,将药渣中再加入1000mL水,慢火主考后熬制15min,固液分离,得到第二药液和药渣,合并第一药液和第二药液即为中药洗液。
使用方法:取上述中药洗液2000mL,浴头并按摩,每日一剂,使药液与头皮充分接触,每次15min,药汁保留不用清洗,待干。
实施例2
一种治疗炎症性皮肤病的中药组合物,由以下重量份数的原料组成:金银花50份、侧柏叶40份、大青叶40份、连翘40份、桑叶30份、薰衣草50份、黑种草子30份、丹参40份、皂角50份。
取上述中药组合物320g,加入3000mL水,浸泡1h,慢火煮开后熬制20min,固液分离,得到第一药液和药渣,将药渣中再加入1000mL水,慢火主考后熬制20min,固液分离,得到第二药液和药渣,合并第一药液和第二药液即为中药洗液。
使用方法:取上述中药洗液2000mL,浴头并按摩,每日一剂,使药液与头皮充分接触,每次15min,药汁保留不用清洗,待干。
实施例3
一种治疗疗炎症性皮肤病的中药组合物,由以下重量份数的原料组成:金银花20份、侧柏叶20份、大青叶20份、连翘30份、桑叶20份、薰衣草20份、黑种草子20份、丹参20份、皂角30份。
取上述中药组合物200g,加入2500mL水,浸泡1h,慢火煮开后熬制20min,固液分离,得到第一药液和药渣,将药渣中再加入1000mL水,慢火主考后熬制20min,固液分离,得到第二药液和药渣,合并第一药液和第二药液即为中药洗液。
使用方法:取上述中药洗液2000mL,浴头并按摩,每日一剂,使药液与头皮充分接触,每次15min,药汁保留不用清洗,待干。
实施例4
唐某,男,病例ID:000XXXXX72,35岁。
主诉:头部起红斑、丘疹、鳞屑,瘙痒反复半年。现病史:患者半年前无明显原因头部起红斑丘疹,脱屑,瘙痒至某医院活检回示为反向型银屑病,口服药不详,外用卡泊三醇搽剂,疗效不佳,为寻求中医治疗,至我科门诊就诊。患者平素汗出较多,纳寐尚可,小便偏黄,大便质黏,舌淡红,苔白腻,脉缓。专科检查:头皮发际线处可见黄豆至核桃大小浸润性红色斑块,上覆银白色鳞屑,刮去鳞屑未见薄膜现象及点状出血,未见束状发及趾指甲改变。西医诊断:寻常型银屑病(静止期)。中医诊断:白疕。中医辨证:脾虚湿蕴证。治法:健脾祛湿,解毒止痒。使用本发明实施例3中的洗液配合中药健脾解毒丸,治疗2个月后,头皮发际线处皮疹消退,无痒感。随访至今未见复发。为确保病患隐私,此处不公布病患身份,患者的身份信息和病例案号存档在新疆维吾尔自治区中医医院,可供查阅。
实施例5
申某,男,病例ID:000XXXXX65,19岁。
主诉:斑片状脱发1月余。现病史:患者半年前无明显原因颞部头发脱落,未治疗,为寻求中医治疗,至我科门诊就诊。患者平素纳食可,睡眠欠佳,多梦易醒,大便粘滞,1日1-2次。舌淡红,苔白,边有齿痕,脉滑。专科检查:颞部2处蚕豆大小头发脱落,发质油性较大。西医诊断:斑秃。中医诊断:油风。中医辨证:脾虚湿蕴证。治法:健脾祛湿,清热解毒。使用中药口服配合本发明实施例3中药洗液治疗1个月后,颞部脱发区可见细软毳毛长出,不易脱落,随访至今未见复发。为确保病患隐私,此处不公布病患身份,患者的身份信息和病例案号存档在新疆维吾尔自治区中医医院,可供查阅。
实施例6本发明的中药组合物的药效临床试验
为了说明本发明的中药洗剂具有防治脂溢性脱发的效果,本发明进行了下列疗效试验。
1.试验基本设计
观察脂溢性脱发患者60例,随机分为两组,治疗组30人,其中男性19例,女性11例,对照组30人,其中男性17例,女性13例,年龄18-60岁,病程1-15年。诊断标准和疗效评价参照2019年制定的《中国人雄激素性脱发诊疗指南》与赵辨主编《中国临床皮肤病学》。试验在新疆维吾尔自治区中医医院(三级甲等医院)进行,为确保病患隐私,此处不公布病患身份,患者的身份信息和病例案号存档在新疆维吾尔自治区中医医院档案室,可供查阅。
2.脂溢性脱发诊断标准
参照《中国人雄激素性脱发诊疗指南》与赵辨主编《中国临床皮肤病学》。
(1)有遗传倾向,多在直系亲属中有家族史。
(2)多数从青春期开始,常发生在20-30岁男性中,女性亦可发生,较男性症状轻。
(3)男性型脱发:头发出现渐进性脱落,脱发区可从前额两侧向头顶延伸,多出现发际线后退伴头发纤细,头皮油腻;或从头顶脱落;或前额和头顶同时脱落。
(4)女性型脱发:脱落进程缓慢,多出现头顶弥漫性脱落,发际线不后退。
3.治疗方案
实验组:取实施例3中的中药洗液,每次用药2000mL,浴头并按摩,每日一剂,使药液与头皮充分接触,每次15分钟,药汁保留不用清洗,待干,每天1次。
对照组:取2%米诺地尔搽剂(浙江万晟药业有限公司国药准字H20010714)涂抹患处,从患处的中心开始涂抹,每次1mL,按摩头皮3~5min,每天1次。
用药疗程:
4周为1个疗程,共2个疗程
4.疗效观察
目前尚无统一的症状评分标准按,参照《中药新药临床研究指导原则》中的积分法拟定如下评分:观察两组患者治疗前后的脱发数目、瘙痒程度、油腻程度、头屑程度及新发生长情况。用量化评分法,每项占1分,分0、1、2、3记分。具体评分方法见表1。
表1观察症状评分
5.疗效判定标准
参照《中药新药临床研究指导原则》疗效指数(尼莫地平法)=[(治疗前总积分-治疗后总积分)/治疗前总积分]×100%。治愈为疗效积分下降≥90%;显效为疗效积分下降≥60%;好转为疗效积分下降≥25%;无效为疗效积分下降<25%。总有效率=临床治愈率+显效率。
5.统计学方法:
应用SPSS26.0进行数据处理与统计分析。计数资料采用卡方检验,计量资料先用正态性检验检测是否为正态分布,组间数据若符合正态分布,用两独立样本t检验,以概率P值是否小于0.05分析统计学意义。
6.结果
6.1一般资料
按照拟定的研究方案,治疗组30人、对照组30人,其中治疗组男性为19人,女性为11人,对照组男性为18人,女性为12人,两组患者的性别、年龄、病程情况差异均无统计学意义。
6.2脱发数目情况积分比较
表5为对照组和治疗组的脱发数目情况比较,由表5分析可以得出,治疗组和对照组治疗前脱发数目情况积分比较(P>0.05),说明两组治疗前脱发数目情况积分比较无差异。治疗组和对照组组间比较:两组治疗两个疗程后,治疗组脱发数目情况积分小于对照组,差异具有统计学意义(P<0.05)。治疗组和对照组组内比较:治疗两个疗程后,两组脱发数目情况积分均小于与治疗前,差异均具有统计学意义(P<0.05)。
表5脱发数目情况积分比较
注:与治疗前比较,*P<0.05
6.3头屑情况积分比较
表6为治疗组和对照组头屑情况积分比较,由表6分析可以得出,治疗组和对照组治疗前头屑情况积分比较(P>0.05),说明两组治疗前头屑情况积分比较无差异。治疗组和对照组组间比较:两组治疗两个疗程后,治疗组头屑情况积分小于对照组,差异具有统计学意义(P<0.05)。治疗组和对照组组内比较:治疗两个疗程后,两组头屑情况积分均小于治疗前积分,差异
表6头屑情况积分比较
注:与治疗前比较,*P<0.05
均具有统计学意义(P<0.05)。
表7为治疗组和对照组油腻程度积分比较,由表7分析可以得出,治疗组和对照组治疗前油腻程度积分比较(P>0.05),说明两组治疗前油腻程度积分比较无差异。治疗组和对照组组间比较:两组治疗两个疗程后,治疗组油腻程度积分小于对照组,差异具有统计学意义(P<0.05)。治疗组和对照组组内比较:治疗两个疗程后,两组油腻程度积分均小于治疗前积分,差异均具有统计学意义(P<0.05)。
表7油腻程度积分比较
注:与治疗前比较,*P<0.05
6.4瘙痒程度积分比较
表8为治疗组和对照组瘙痒程度积分比较,由表8分析可以得出,治疗组和对照组治疗前瘙痒程度积分比较(P>0.05),说明两组治疗前瘙痒程度积分比较无差异。治疗组和对照组组间比较:两组治疗两个疗程后,治疗组瘙痒程度积分小于对照组,差异具有统计学意义(P<0.05)。治疗组和对照组组内比较:治疗两个疗程后,两组瘙痒程度积分均小于治疗前积分,差异均具有统计学意义(P<0.05)。
表8瘙痒程度积分比较
注:与治疗前比较,*P<0.05
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (7)
1.一种治疗炎症性皮肤病的中药组合物,其特征在于,由以下重量份的原料组成:金银花15~50份、侧柏叶15~40份、大青叶15~40份、连翘25~40份、桑叶15~30份、薰衣草15~50份、黑种草子15~30份、丹参15~40份、皂角25~50份。
2.根据权利要求1所述的中药组合物,其特征在于,由以下重量份的原料组成:金银花15~25份、侧柏叶15~25份、大青叶15~25份、连翘25~35份、桑叶15~25份、薰衣草15~25份、黑种草子15~25份、丹参15~25份、皂角25~35份。
3.根据权利要求1所述的中药组合物,其特征在于,由以下重量份的原料组成:金银花20份、侧柏叶20份、大青叶20份、连翘30份、桑叶20份、薰衣草20份、黑种草子20份、丹参20份、皂角30份。
4.一种治疗炎症性皮肤病的中药洗剂,其特征在于,由以下方法制备得到:
将权利要求1~3任意一项所述中药组合物与水混合进行煎煮,所得煎煮液为中药洗剂。
5.根据权利要求4所述的洗剂,其特征在于,所述中药组合物与水的用量比为155g:1500~3000mL。
6.根据权利要求4所述的洗剂,其特征在于,所述中药组合物与水混合后浸泡1~2h再进行煎煮。
7.根据权利要求4所述的洗剂,其特征在于,所述煎煮的时间为15~20min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210831353.0A CN115025150B (zh) | 2022-07-14 | 2022-07-14 | 一种治疗炎症性皮肤病的中药组合物、洗剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210831353.0A CN115025150B (zh) | 2022-07-14 | 2022-07-14 | 一种治疗炎症性皮肤病的中药组合物、洗剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115025150A CN115025150A (zh) | 2022-09-09 |
CN115025150B true CN115025150B (zh) | 2023-05-16 |
Family
ID=83128605
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210831353.0A Active CN115025150B (zh) | 2022-07-14 | 2022-07-14 | 一种治疗炎症性皮肤病的中药组合物、洗剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115025150B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115444917B (zh) * | 2022-10-26 | 2024-05-24 | 新疆医科大学第四附属医院 | 一种治疗湿疹的中药组合物、中药乳膏剂及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112826900A (zh) * | 2021-03-08 | 2021-05-25 | 上海市宝山区淞南镇社区卫生服务中心 | 一种治疗脂溢性脱发的中药组合物及其药物制剂 |
CN114159531A (zh) * | 2021-12-13 | 2022-03-11 | 北京中医药大学第三附属医院 | 控油、祛屑、止痒、固发、生发组合物、制备方法及应用 |
-
2022
- 2022-07-14 CN CN202210831353.0A patent/CN115025150B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112826900A (zh) * | 2021-03-08 | 2021-05-25 | 上海市宝山区淞南镇社区卫生服务中心 | 一种治疗脂溢性脱发的中药组合物及其药物制剂 |
CN114159531A (zh) * | 2021-12-13 | 2022-03-11 | 北京中医药大学第三附属医院 | 控油、祛屑、止痒、固发、生发组合物、制备方法及应用 |
Non-Patent Citations (1)
Title |
---|
徐灿坤.程益春教授治疗脱发的经验.国医论坛.-,2002,第17卷(第03期),9-10. * |
Also Published As
Publication number | Publication date |
---|---|
CN115025150A (zh) | 2022-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102139030A (zh) | 一种治疗牙龈炎的口腔中药制剂及其制备方法 | |
CN103463539A (zh) | 一种治疗湿疹的药物及其制备方法和用途 | |
CN101554424B (zh) | 一种治疗皮肤病的中药及其制备方法 | |
CN115025150B (zh) | 一种治疗炎症性皮肤病的中药组合物、洗剂 | |
CN106728898A (zh) | 一种修复皮肤屏障的药物组合物及其制备方法 | |
CN116672383B (zh) | 一种治疗湿疹的中药组合物及其应用 | |
CN105213557A (zh) | 一种治疗湿疹的中药组合物 | |
CN115154521B (zh) | 一种治疗外寒内热引发银屑病的组合物、制剂及制备方法 | |
CN115252691B (zh) | 一种用于治疗气滞血瘀型冠心病心绞痛的中药组合物 | |
CN108434226A (zh) | 一种治疗斑秃、脂溢性脱发的抑菌水剂及其制备方法 | |
AU2020408730A1 (en) | Traditional chinese medicine composition for treating EGFR-TKIs related skin rash and use thereof | |
CN105343847A (zh) | 一种含有艾叶的治疗湿疹的中药组合物及其制备方法 | |
CN107617081B (zh) | 一种治疗脱发的中药组合物及其制剂与制备方法 | |
Khan | An exploration into the management and diagnosis of Polycystic Ovarian Syndrome by Complementary and Alternate Medical (CAM) practitioners in the eThekwini area | |
CN114848558B (zh) | 一种防脱生发、白发转黑发的生发乌发液及其制备方法 | |
CN112675264B (zh) | 治疗银屑病的组合物、制备方法及其应用 | |
CN114504619B (zh) | 一种治疗特应性皮炎的中药组合物 | |
CN113384636B (zh) | 一种外用治疗婴幼儿儿童特应性皮炎的消炎止痒中药配方及使用方法 | |
CN109568182B (zh) | 一种茶油小儿舒润膏 | |
CN105169342A (zh) | 一种治疗湿疹的中药组合物及其制备方法 | |
CN105250433A (zh) | 用于治疗痔疮的外用中药膏剂及其制作方法 | |
CN118178559A (zh) | 一种治疗肛窦炎的中药组合物及其制备方法和用途 | |
CN118320036A (zh) | 一种治疗外阴苔藓样变的中药洗剂配方 | |
CN118203641A (zh) | 一种预防和/或治疗急性放射性皮炎的外用中药组合及制备方法 | |
CN118680971A (zh) | 一种能抑菌消炎的彝药口香糖及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |